Oncologic Drugs Advisory Committee to Discuss Johnson & Johnson and Legend Biotech Biologics License Application

Silver Spring, Maryland – On Friday, the FDA’s Oncologic Drugs Advisory Committee will convene to review Johnson & Johnson and Legend Biotech Corporation’s joint application for Carvykti, a treatment for patients with relapsed or refractory multiple myeloma. This particular session aims to assess the risks and benefits of Carvykti, specifically looking at the results of the CARTITUDE-4 trial to determine its efficacy in this patient population. The main focus of the discussion will be on …

Read more